Zhitong Biopharmaceutical

Zhejiang Zhitong Biopharmaceutical is a clinical-stage biotechnology company specializing in the development of long-acting recombinant protein therapeutics. Headquartered in Huzhou, China, the company utilizes proprietary technology platforms to enhance the pharmacokinetic properties and therapeutic windows of established biologics. Its pipeline is primarily focused on hematology and metabolic diseases, with lead candidates including long-acting versions of granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO). Zhitong Biopharmaceutical maintains integrated capabilities that encompass drug discovery, process development, and large-scale GMP manufacturing. The company aims to provide high-quality, affordable bio-better drugs to patients globally.